• Baymatob

  Led · Grant · Aug 2019

  Baymatob develops Oli, a wireless, wearable device that monitors maternal and fetal signals and aims to analyse up to fifteen pregnancy and birth conditions and complications. Targeted conditions include postpartum haemorrhage, fetal distress, stillbirth risk and labour progression. The company is conducting pivotal clinical trials across seven sites in Australia and the United States and is advancing regulatory submissions with the TGA and FDA. Baymatob plans to establish manufacturing operations and its headquarters in Australia. Financially, the company has raised $13 million in private capital plus more than $9.5 million in non-dilutive grants and completed a $6.5 million Series A3 in 2025.

• Indee Labs

  Led · Equity · Aug 2018

  Indee Labs is a seed-stage biotechnology company based in Berkeley, Calif., developing the µVS Delivery SystemTM for non-viral intracellular and gene delivery with a focus on T cell immunotherapy manufacturing. The company says µVS enables high yield of modified cells, rapid processing of tens of millions of cells in seconds, and negligible perturbation of immune cell state. Indee Labs has published results in Nature Scientific Reports and bioRxiv demonstrating improvements over existing methods. With funding from NIAID/NIH, the company is developing the µVS platform to engineer antigen-specific regulatory T cells (Tregs). Its stated goal is to demonstrate utility to prevent graft-versus-host disease (GvHD) in preclinical models and to offer a scalable alternative to viral- and electroporation-based cell manufacturing. Indee Labs collaborates with multiple pharmaceutical and biotechnology companies and is backed by accelerator and VC backers including IndieBio/SOSV, Y Combinator, Social Capital, Main Sequence Ventures, and Founders Fund’s FF Science among others. Indee Labs is developing hardware for gene delivery using microfluidic vortex shedding (µVS) to mechanically and gently permeabilize cell membranes and deliver genetic material such as mRNA into T cells. The company’s approach is positioned as an alternative to viral vectors and electroporation, with lab tests showing it can be faster, safer and more scalable. Indee Labs has demonstrated delivery into human white blood cells/T cells and aims to simplify manufacturing to improve access to curative therapies for blood cancers. The firm is pursuing partnerships with biopharma and academic groups and is trialing its technology in a preclinical study with the University of Sydney. The work is intended to enable open-source biology approaches for gene-modified cell therapy manufacturing and support future clinical translation. Indee Labs is backed by investors in Australia and the U.S., and is led in Australia by CEO Dr Warren McKenzie. Indee Labs develops hardware for gene delivery using microfluidic vortex shedding (µVS) to accelerate gene-therapy manufacturing and discovery-stage research. Its µVS platform reportedly delivers higher yield, rapid processing, negligible immune-cell perturbation, and a small-footprint workflow. Transcriptome-wide sequencing data showed negligible differential gene expression in over 200,000 unique transcript reads, and additional studies revealed no variation in cytokine production or activation phenotype versus handling controls. The company plans to commercialize a user-friendly instrument and conduct head-to-head studies against incumbent technologies to demonstrate performance improvements. Proceeds from recent funding will be used to build the team, advance instrument development, and support comparative studies; a BioMedTech Horizons grant will fund Australian operations and chip development at the ANFF and UniSA’s Future Industries Institute. Indee Labs aims to reduce treatment lead times from months to weeks or days and enable faster, potentially bedside, cell-therapy workflows.

No current team members are available.